(see Note 10, Investments) and (ii) net impairment charges on intangible assets (see Note 13, Goodwill and other intangible assets). For the year ended December 31, 2023, other segment items also included expenses related to our restructuring plan that was both initiated and substantially completed in 2023. For the year ended December 31, 2022, other segment items also included a loss on the divestiture of Gensenta (see Note 4, Acquisitions and divestitures).
F-15
3.
Revenues
We operate our business in
one
operating segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customersâ€™ locations, are presented below. The majority of ROW product sales relates to products sold in Europe.
Revenues were as follows (in millions):
____________
(1)
TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on October 6, 2023, and include product sales in the periods after the acquisition date.
(2)
Consists of product sales of our non-principal products.
(3)
Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2024, 2023 and 2022.
In the United States, we sell primarily to pharmaceutical wholesale distributors that we use as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance.
F-16
For each of the years ended December 31, 2024, 2023 and 2022, we had product sales to three customers that individually accounted for more than 10% of total revenues.
For the year ended December 31, 2024, on a combined basis, these customers accounted for
77
% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):
As of December 31, 2024 and 2023, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for
70
% and
75
%, respectively, of net trade receivables on a combined basis. As of December 31, 2024 and 2023,
26
% and
22
%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2024 and 2023, was not material.
F-17
4.
Acquisitions and divestitures
Acquisition of Horizon Therapeutics plc
On October 6, 2023, Amgen completed its acquisition of Horizon by acquiring all of the outstanding shares of Horizon for $
116.50
per share in cash, representing a total